Business Medical Dialogues
    • facebook
    • twitter
    Login Register
    • facebook
    • twitter
    Login Register
    • Medical Dialogues
    • Speciality Dialogues
    • Education Dialogues
    • Medical Jobs
    • Medical Matrimony
    • MD Brand Connect
    Business Medical Dialogues
    • News
        • Financial Results
        • Hospitals & Diagnostics
        • IT / Health Venture
        • Implants / Devices
        • Insurance
        • Key Movement
        • Pharmaceuticals
        • Policy
        • Technology
        • pharma-news
    • blog
    LoginRegister
    Business Medical Dialogues
    LoginRegister
    • Home
    • News
      • Financial Results
      • Hospitals & Diagnostics
      • IT / Health Venture
      • Implants / Devices
      • Insurance
      • Key Movement
      • Pharmaceuticals
      • Policy
      • Technology
      • pharma-news
    • blog
    • Home
    • Editors Pick
    • Intas Pharma cuts down...

    Intas Pharma cuts down price of cancer drug Bevacizumab by 60 percent

    Written by Ruby Khatun Khatun Published On 2017-10-06T11:12:18+05:30  |  Updated On 14 Aug 2021 11:29 AM IST

    AHMEDABAD: Intas Pharmaceuticals Limited, announced that the company is cutting down the cost of the cancer drug Bevacizumab by 60 percent in order to bring relief to a large number of cancer patients in the country for whom the drug was out of reach.


    The drug bevacizumab is now priced at Rs. 39,995 for the dose strength of 400 mg variant which makes it 60% less than the currently available options.


    Every year, over 7 lakh patients die due to various types of cancer in India. Intas believes in the philosophy of 'Patient First'. Hence, in order to relieve the patients from the financial burden associated with the treatment, this cost-effective measure is implemented by the organization.


    The step is entirely focussed on making the drug treatment accessible to cancer patients in India thus, providing them with a beacon of hope in their fight against the disease.


    Bevacizumab is a drug that works by slowing the growth of new blood vessels and is used in treating multiple cancers like colorectal cancer, ovarian cancer, cervical cancer, lung cancer and recurrent glioblastoma (a type of brain tumour).


    The drug has been available in India since 2004 but the cost has been so prohibitive that as per eminent clinicians of the country, they have been able to give this drug to very few eligible patients.


    Intas is a leading, vertically integrated global pharmaceutical company from India, having end-to-end capabilities of formulation development, manufacturing, and marketing along with the backward integration of APIs.


    Intas' success and incessant growth focus lie in its clinical execution of successful and strategic moves made in the areas of manufacturing, R&D, biotechnology and global operations over the past three decades.


    Intas has been growing at 27% CAGR over the last 5 years with an even stronger profit growth. Ranked 10th in the domestic market, the company is one of the top 5 corporates in the Indian Chronic Therapy category.


    Intas is also present in more than 70 countries worldwide with robust sales, marketing and distribution infrastructure in markets like North America, Europe, Central and Latin America, Africa, Australia, New Zealand, Asia Pacific as well as CIS and MENA countries.

    bevacizumabbiosimilarbrain tumourcancer drugcancerscervical cancercolorectal cancerHealthcareHealthcare NewsIndiaindian pharma newsIntas PharmaIntas Pharmaceuticalslower costlung cancerovarian cancerpharma newspharma news indiapricesrecurrent glioblastoma
    Source : Press Release

    Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd

    Ruby Khatun Khatun
    Ruby Khatun Khatun
      Show Full Article
      Next Story
      Similar Posts
      NO DATA FOUND

      Popular Stories

      • Email: info@medicaldialogues.in
      • Phone: 011 - 4372 0751

      Website Last Updated On : 13 Oct 2022 5:14 AM GMT
      Company
      • About Us
      • Contact Us
      • Our Team
      • Reach our Editor
      • Feedback
      • Submit Article
      Ads & Legal
      • Advertise
      • Advertise Policy
      • Terms and Conditions
      • Privacy Policy
      • Editorial Policy
      • Comments Policy
      • Disclamier
      Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

      Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2025 Minerva Medical Treatment Pvt Ltd

      © 2025 - Medical Dialogues. All Rights Reserved.
      Powered By: Hocalwire
      X
      We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok